GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Gross Margin %

QuidelOrtho (QuidelOrtho) Gross Margin %

: 51.35% (As of Dec. 2023)
View and export this data going back to 1992. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. QuidelOrtho's Gross Profit for the three months ended in Dec. 2023 was $381 Mil. QuidelOrtho's Revenue for the three months ended in Dec. 2023 was $743 Mil. Therefore, QuidelOrtho's Gross Margin % for the quarter that ended in Dec. 2023 was 51.35%.

Warning Sign:

QuidelOrtho Corp gross margin has been in long-term decline. The average rate of decline per year is -3%.


The historical rank and industry rank for QuidelOrtho's Gross Margin % or its related term are showing as below:

QDEL' s Gross Margin % Range Over the Past 10 Years
Min: 49.85   Med: 59.85   Max: 81.17
Current: 49.85


During the past 13 years, the highest Gross Margin % of QuidelOrtho was 81.17%. The lowest was 49.85%. And the median was 59.85%.

QDEL's Gross Margin % is ranked worse than
56.77% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 53.54 vs QDEL: 49.85

QuidelOrtho had a gross margin of 51.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for QuidelOrtho was -3.00% per year.


QuidelOrtho Gross Margin % Historical Data

The historical data trend for QuidelOrtho's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 59.98 [6] => 81.17 [7] => 75.26 [8] => 59.28 [9] => 49.85 )
QuidelOrtho Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.98 81.17 75.26 59.28 49.85

QuidelOrtho Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.82 53.02 44.56 49.48 51.35

Competitive Comparison

For the Medical Devices subindustry, QuidelOrtho's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QuidelOrtho Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, QuidelOrtho's Gross Margin % distribution charts can be found below:

* The bar in red indicates where QuidelOrtho's Gross Margin % falls into.



QuidelOrtho Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

QuidelOrtho's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1494.4 / 2997.8
=(Revenue - Cost of Goods Sold) / Revenue
=(2997.8 - 1503.4) / 2997.8
=49.85 %

QuidelOrtho's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=381.3 / 742.6
=(Revenue - Cost of Goods Sold) / Revenue
=(742.6 - 361.3) / 742.6
=51.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


QuidelOrtho  (NAS:QDEL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

QuidelOrtho had a gross margin of 51.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


QuidelOrtho Gross Margin % Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


QuidelOrtho (QuidelOrtho) Business Description

Traded in Other Exchanges
Address
9975 Summers Ridge Road, San Diego, CA, USA, 92121
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Executives
Louise Brandy officer: SVP, Chief Information Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein officer: Chief Administrative Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith director 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael director 618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy officer: SVP, Cardio/Metabolic Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll officer: SVP, Research and Development 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler director
Robert R. Schmidt director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli officer: SVP, Molecular Bus. Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski officer: See Remarks C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr. director 82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges officer: SVP, General Counsel 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant director, officer: Chairman & CEO C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015